# BMRN catalysts: BIOMARIN PHARMACEUTICAL INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/bmrn/catalysts

> BIOMARIN PHARMACEUTICAL INC (BMRN) has 10 upcoming catalysts. The next is the VOXZOGO (vosoritide) PDUFA date, February 28, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for BMRN?

BIOMARIN PHARMACEUTICAL INC (BMRN) has 10 upcoming catalysts. The next is the VOXZOGO (vosoritide) PDUFA date, February 28, 2027. SEC Form 10-Q: "•In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a PDUFA target action date of February 28, 2027." [Calendar and source filings](https://sec-api.dev/companies/bmrn/catalysts)

Source: SEC Form 10-Q, accession 0001048477-26-000023, https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/bmrn-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/companies/bmrn/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | BIOMARIN PHARMACEUTICAL INC |
| Ticker | BMRN (Nasdaq) |
| SEC CIK | 1048477 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/bmrn |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 19, 2025 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "SAN RAFAEL, Calif., February 19, 2025 - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847725000004/earningsrelease-19feb25ex9.htm)) |
| May 1, 2025 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847725000049/earningsrelease-1may25ex991.htm)) |
| 2H 2025 | [BIOMARIN PHARMACEUTICAL INC interim data readout](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | scheduled | "Initial data for BMN 351 is anticipated to be presented at a scientific congress in the second half of 2025 (including muscle dystrophin levels from the 6 mg/kg cohort after 25 weeks of dosing)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847725000049/earningsrelease-1may25ex991.htm)) |
| August 4, 2025 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance1 for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/earningsrelease-04aug25ex9.htm)) |
| October 27, 2025 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847725000104/earningsrelease-27oct25ex9.htm)) |
| 1H 2026 | [INZ-701 trial start](https://sec-api.dev/pdufa/inz-701) | BMRN |  | scheduled | "Based on these results, BioMarin is advancing plans to initiate the registration-enabling Phase 2/3 study in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/earningsrelease-04aug25ex9.htm)) |
| 1H 2026 | [VOXZOGO (vosoritide) topline data readout](https://sec-api.dev/pdufa/vosoritide) | BMRN |  | scheduled | "With VOXZOGO in hypochondroplasia, the company expects to share topline data from its pivotal study in the first half of 2026 and file submissions to global health authorities for approval in the second half of 2026, leading to a potential launch in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/earningsrelease-04aug25ex9.htm)) |
| 1H 2026 | [INZ-701 interim data readout](https://sec-api.dev/pdufa/inz-701) | BMRN |  | scheduled | "Initial pivotal data readout for the ENERGY 3 study in children ages 1-12 years is anticipated in the first half of 2026, with potential launch in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/earningsrelease-04aug25ex9.htm)) |
| early 2026 | [INZ-701 topline data readout](https://sec-api.dev/pdufa/inz-701) | BMRN |  | scheduled | "First Pivotal Data Readout in Children Expected in Early 2026 with" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000119312525121296/d833625dex991.htm)) |
| January 12, 2026 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "BioMarin expects to report its results for the fourth quarter and full year 2025 in February 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/d93149dex991.htm)) |
| February 23, 2026 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "SAN RAFAEL, Calif., February 23, 2026 - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000002/earningsrelease-23feb26ex9.htm)) |
| February 28, 2026 | [BIOMARIN PHARMACEUTICAL INC PDUFA date](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | scheduled | "•U.S. PDUFA date for the adolescent label expansion February 28, 2026; EU approval 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000002/earningsrelease-23feb26ex9.htm)) |
| April 23, 2026 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Hypochondroplasia | completed | "NCT06455059 (Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-23 (ACTUAL); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06455059)) |
| May 4, 2026 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "SAN RAFAEL, Calif., May 4, 2026 - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the first quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000006/earningsrelease-4may26ex991.htm)) |
| June 2026 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Idiopathic Short Stature | delayed | "NCT06382155 (A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-06 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06382155)) |
| Jul 2026 | [VOXZOGO (vosoritide) NDA/BLA submission](https://sec-api.dev/pdufa/vosoritide) | BMRN | hypochondroplasia | completed | "•In July 2026, we submitted our supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of VOXZOGO for the treatment of hypochondroplasia following our announcement in May 2026 that the Phase 3 CANOPY-HCH-3 study met its primary endpoint." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000016/bmrn-20260630.htm)) |
| August 6, 2026 | [VOXZOGO (vosoritide) NDA/BLA acceptance](https://sec-api.dev/pdufa/vosoritide) | BMRN | achondroplasia | completed | "•In July, BioMarin announced that the FDA accepted its sNDA for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm)) |
| August 6, 2026 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "SAN RAFAEL, Calif., August 6, 2026 - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm)) |
| September 16, 2026 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Noonan Syndrome | withdrawn | "NCT06668805 (A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-16 (ACTUAL); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06668805)) |
| November 2, 2026 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "SAN RAFAEL, Calif., November 2, 2026 - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000021/earningsrelease-2nov26ex991.htm)) |
| February 28, 2027 | [VOXZOGO (vosoritide) PDUFA date](https://sec-api.dev/pdufa/vosoritide) | BMRN | achondroplasia | scheduled | "•In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a PDUFA target action date of February 28, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/bmrn-20260930.htm)) |
| May 30, 2027 | [VOXZOGO (vosoritide) PDUFA date](https://sec-api.dev/pdufa/vosoritide) | BMRN | Hypochondroplasia | scheduled | "PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (HCH)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000021/earningsrelease-2nov26ex991.htm)) |
| December 2027 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Achondroplasia | scheduled | "NCT02724228 (A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02724228)) |
| Dec 2027 to Mar 2028 | [VOXZOGO (vosoritide) topline data readout](https://sec-api.dev/pdufa/vosoritide) | BMRN | Achondroplasia | scheduled | "NCT02724228 (A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02724228)) |
| December 2027 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Achondroplasia | scheduled | "NCT04554940 (A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04554940)) |
| Dec 2027 to Mar 2028 | [VOXZOGO (vosoritide) topline data readout](https://sec-api.dev/pdufa/vosoritide) | BMRN | Achondroplasia | scheduled | "NCT04554940 (A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04554940)) |
| Jun to Sep 2028 | [VOXZOGO (vosoritide) topline data readout](https://sec-api.dev/pdufa/vosoritide) | BMRN | Hypochondroplasia | scheduled | "NCT07126262 (A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07126262)) |
| June 2028 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Hypochondroplasia | scheduled | "NCT07126262 (A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07126262)) |
| June 2029 | [BMN-333 primary completion](https://sec-api.dev/pdufa/bmn-333) | BMRN | Achondroplasia | scheduled | "NCT07441876 (Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441876)) |
| Jun to Sep 2029 | [BMN-333 topline data readout](https://sec-api.dev/pdufa/bmn-333) | BMRN | Achondroplasia | scheduled | "NCT07441876 (Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441876)) |

## Drugs

- [BMN-333](https://sec-api.dev/pdufa/bmn-333): Achondroplasia
- [INZ-701](https://sec-api.dev/pdufa/inz-701): 
- [VOXZOGO (vosoritide)](https://sec-api.dev/pdufa/vosoritide): achondroplasia, hypochondroplasia, hch, the first potential targeted therapy for the condition, Idiopathic Short Stature, Noonan Syndrome

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/bmrn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BMRN catalysts: BIOMARIN PHARMACEUTICAL INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/bmrn/catalysts

```bibtex
@misc{secapidev_companies_bmrn_catalysts_20261116,
  title        = {BMRN catalysts: BIOMARIN PHARMACEUTICAL INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/bmrn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_bmrn_catalysts_20261116","title":"BMRN catalysts: BIOMARIN PHARMACEUTICAL INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/bmrn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
